SCHEMBL19355355

SCHEMBL19355355

COc1ccccc1CCNc1cc(-c2ccc(NC3CCN(C)CC3)nc2)ncn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 12/20 0.47
CYP3A4 P08684 11/20 0.47
CYP2D6 P10635 10/20 0.47
CYP2C19 P33261 10/20 0.47
CLK4 Q9HAZ1 9/20 0.47
TSHR P16473 9/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPK1 P28482 5/20 0.47
GSK3B P49841 2/20 0.47
CHEK1 O14757 1/20 0.47
IKBKB O14920 1/20 0.47
AURKA O14965 1/20 0.47
PAK4 O96013 1/20 0.47
CHEK2 O96017 1/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
INSR P06213 1/20 0.47
LCK P06239 1/20 0.47
FGFR1 P11362 1/20 0.47
SELP P16109 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19355418 0.91 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL20373137 0.84 CYP3A4 (0.42) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL17634517 0.84 CYP3A4 (0.42) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL19355250 0.84 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL15342939 0.83 CYP1A2 (0.49) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL19905240 0.82 SYK (0.41) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL16664942 0.81 SYK (0.49) GSK3BTYRO3IKBKESYKFLT3
SCHEMBL15343334 0.81 JAK2 (0.50) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL19905387 0.80 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL15343097 0.80 CYP1A2 (0.52) CYP1A2CYP3A4CYP2D6CYP2C19CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CYP1A2 2215/4885CYP3A4 1759/4885CYP2D6 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.